Switching from Originator Tocilizumab to Biosimilar in Giant Cell Arteritis: Evaluation of Effectiveness and Safety in a Multicenter Cohort of 38 Patients - PubMed
a day ago
- #Tocilizumab
- #Biosimilar
- #Giant Cell Arteritis
- Study evaluates switching from originator Tocilizumab (RoACTEMRA™) to biosimilar (TYENNE™) in Giant Cell Arteritis (GCA).
- 38 patients (68.4% female, mean age 74.1 years) with GCA were included in this multicenter, retrospective study.
- Prior exposure to RoACTEMRA™ averaged 36.3 months, with 92.1% asymptomatic and 81.6% in complete remission at switch.
- No significant differences in complete remission rates, prednisone dose, or inflammatory markers were found after 8.2 months follow-up.
- Biosimilar retention rate was 94.7%, with no disease relapses reported. Safety profile included one case of herpes zoster and one discontinuation due to diverticulosis.
- Switching to biosimilar TCZ appears safe and effective in GCA patients in routine clinical practice.